Physician profile
Katrina Walsh
NPI 1073502563
$1,483.27
in general payments reported to CMS, 2019-2025
13 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $106 · 2024: $600 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $800.00 | 2024-2025 | |
| Celularity INC. | $300.00 | 2019 | |
| Amgen INC. | $134.97 | 2019-2020 | |
| Abbvie INC. | $44.52 | 2019-2020 | |
| Therapeuticsmd, INC. | $41.50 | 2019 | |
| Pfizer INC. | $40.29 | 2019-2020 | |
| Duchesnay USA Incorporated | $25.61 | 2019 | |
| Exeltis, USA INC. | $19.22 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.54 | 2019 | |
| Millicent US INC | $16.50 | 2019 | |
| Bausch Health US, LLC | $16.22 | 2019 | |
| Avion Pharmaceuticals | $14.39 | 2020 | |
| Currax Pharmaceuticals LLC | $13.51 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.